Quarterly Sales (approved)
August 10, 2020
Amp Volatility Score
Catalyst Info & Data Links
TITLE: Bempedoic acid (Nexletol) in LDL-C (FDA-approved drug) - Quarterly Sales
WHAT IS THE CATALYST EVENT?
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
07-01-2020 Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients with Hypercholesterolemia Journal of the American Medical Association Cardiology,
2019: Safety and efficacy of bempedoic acid to reduce LDL cholesterol. New England Journal of Medicine, 380(11), 1022-1032.
2019: Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. Journal of the American Heart Association, 8(7), e011662.
2020: Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. European journal of preventive cardiology, 27(6), 593-603.
Crestor® (rosuvastatin calcium) - AstraZeneca
Lipitor® (atorvastatin) - Pfizer Inc.
Lipostat® - Bristol-Myers Squibb
Pravachol® (pravastatin sodium) - Bristol-Myers Squibb
~ 62.6 M US adults have elevated levels of LDL-C (also known as hypercholesterolemia)
~ 27.4 M US adults with elevated LDL-C levels are taking a statin
~ 19.4 M patients with elevated LDL-C levels are currently unable to achieve their LDL-C targetdespite taking statin therapy
MECHANISM OF ACTION/RATIONALE
Bempedoic acid is an adenosine triphosphate-citrate lyase (ACL) inhibitor that lowers low-density lipoprotein cholesterol (LDL-C) by inhibition of cholesterol synthesis in the liver. ACL is an enzyme upstream of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase in the cholesterol biosynthesis pathway. Bempedoic acid and its active metabolite, ESP15228, require coenzyme A (CoA) activation by very long-chain acyl-CoA synthetase 1 (ACSVL1) to ETC-1002-CoA and ESP15228-CoA, respectively. ACSVL1 is expressed primarily in the liver. Inhibition of ACL by ETC-1002-CoA results in decreased cholesterol synthesis in the liver and lowers LDL-C in blood via upregulation of low-density lipoprotein receptors. (Source)
Updated by HC
ESPR, Bempedoic Acid, Nexletol, LDL-C, Elevated LDL-C, high cholestrol, Quarterly Sales
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post